Skip To Main Content
Jason Pugh on Muck Rack

Jason Pugh

United Kingdom
Covers:  Peptides, longevity, senolytics, GLP-1 receptor agonists, nootropics and biohacking. Evidence-led coverage of supplement quality, contamination and what the human trials actually show.
Doesn't Cover: No product launches, testimonials or influencer stories. No general fitness, diet or nutrition. Nothing without published human data.
🧬 Biohacking | Longevity | Peptides Science-backed protocols for human optimisation 🔬 Evidence, not hype. Not medical advice. humanupgradeai.com

Get in touch with Jason

Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Jason Pugh’s Biography

Read Full Bio →

I'm the founder and editor of HumanUpgradeAI, a UK publication covering peptides, longevity, nootropics and metabolic optimisation for readers who want the evidence rather than the marketing.

I started it because most writing in this field falls into one of two failure modes: supplement copy that treats a mouse study as a human result, or blanket dismissal that treats every compound as quackery. Neither helps someone
deciding what to put in their body.

Every article is built against a verifie…

Jason Pugh’s Journalist Portfolio

See all →
Spermidine and Autophagy: Strong in Mice, Null in Humans

Spermidine and Autophagy: Strong in Mice, Null in Humans

Spermidine extends lifespan in yeast, flies and mice. The SmartAge human trial found no cognitive benefit. Wh…

View article →
Peptide Longevity Statistics 2026: Trials, Market & Data

Peptide Longevity Statistics 2026: Trials, Market & Data

Peptide longevity statistics 2026 reveal 1,872 clinical trials, $48.9 bn market size and 412% GLP-1 growth. L…

View article →
FDA Peptide Reclassification 2026: UK & EU Guide

FDA Peptide Reclassification 2026: UK & EU Guide

The FDA Peptide Reclassification 2026 ends US compounding of 40+ peptides. This guide explains UK & EU legal …

View article →
Peptide Contamination Risks & Quality Testing Guide 2026

Peptide Contamination Risks & Quality Testing Guide 2026

Learn the real peptide contamination risks affecting 15–40% of batches. Discover how UK researchers use indep…

View article →
Retatrutide vs Tirzepatide: The Comparative Evidence

Retatrutide vs Tirzepatide: The Comparative Evidence

Phase 2 trials and network meta-analyses put retatrutide ahead of tirzepatide on mean weight loss. No head-to…

View article →
GHK-Cu Peptide Reverses Skin Ageing 20-30% in Trials

GHK-Cu Peptide Reverses Skin Ageing 20-30% in Trials

Discover how GHK-Cu peptide reverses skin ageing 20-30% in human trials, boosts collagen 50-70%, accelerates …

View article →

Articles

Peptide & Longevity Statistics 2026

|
By Jason Pugh
| humanupgradeai.com
Peptide & longevity statistics 2026 – a compiled snapshot of the market, clinical evidence and regulation behind therapeutic peptides and longevity compounds. Every figure below is sourced to a primary reference (see References) and was verified against source in July 2026. Cite this page HumanUpgradeAI (2026). Peptide & Longevity Statistics 2026. https://humanupgradeai.com/peptide-longevity-statistics-2026/ Figures compiled from primary sources (see References). Last updated July 2026.
Open in Who Shared Issue with article?

FDA Peptide Reclassification 2026: UK & EU Impact

|
By Human UpgradeAi, Jason Pugh
| humanupgradeai.com
Regulation of Compounded Peptides governs access to custom peptide formulations through licensed pharmacies in the United States. Strict federal limits prevent 503A facilities from using most bulk substances unless those peptides appear on the official FDA shortage list or the 503B Bulk Drug Substance list. Clinicians navigate patient-specific rules, cGMP standards, and enforcement trends that reshape daily prescribing decisions.
Open in Who Shared Issue with article?

Peptide Contamination Risks and Quality Testing

|
By Human UpgradeAi, Jason Pugh
| humanupgradeai.com
Peptide purity, contamination and quality testing of compounded preparations remains a critical concern for anyone sourcing research materials or compounded GLP-1 analogues. Recent analytical work reveals measurable differences between originator products and follow-on versions, including new impurity patterns and variable active content. These deviations can alter stability, immunogenicity and clinical effect.
Open in Who Shared Issue with article?
See all 8 articles